Antibody Sample Clauses

Antibody. For clarity, the Lead Success Factors for each Lead will include a requirement that the relevant Hit (or antibody that comprises the sequence of a Hit or is derived through Mutagenesis of a Hit) induces a functional response or response via an acceptable Target-specific mechanism.
Antibody. The term
Antibody. The term “Antibody” shall mean any antibody and any fragment thereof, including any protein or any fragments thereof and any non-protein based scaffold.
Antibody. The termFirst Antibody” shall mean, individually and collectively, the antibodies against PD-1 described in Exhibit B.
Antibody. Net Profits (including Development Costs - see example below) on sales of the IL-1 Antibody Product in the Co-Commercialization Countries in the IL-1 Antibody Territory to be shared 55% to Novartis, 45% to Regeneron. An example of this would be: NVS RGEN 55% 45% Net Sales 100.0 COGS (10.0) ----- Gross Margin 90.0 49.5 40.5 Expenses (50.0) (27.5) (22.5) ----- ----------------- Net Profit (Before Dev. Costs) 40.0 22.0 18.0 Post-Phase IIB Development Costs (10.0) (5.5) (4.5) ----- ----------------- Net Profit 30.0 16.5 13.5 ===== =================
Antibody. The termFirst Antibody” shall mean, individually and collectively, the anti-PD-1 antibody clones listed in Exhibit B, and all Modifications thereof. To the extent that any Patent Rights in the Enumeral IP include any claim(s) that relate to any antibody other than those listed in Exhibit B, the First Antibody shall be limited the particular antibody clones listed in Exhibits B, and any Modifications thereof.
Antibody. Novartis Regeneron -------- --------- Region Percentage Percentage ------ ---------- ---------- ---------------------------------------------- NAFTA [****] [*****] ----------------------------------------------
Antibody. Regeneron may terminate this Agreement with respect to the entire Territory for IL-1 Antibody Products, on (i) nine (9) months' written notice to Novartis at any time prior to the first Launch of such IL-1 Antibody Product in the IL-1 Antibody Territory; and (ii) twelve (12) months' written notice to Novartis at any time after the first Launch of such IL-1 Antibody Product in the IL-1 Antibody Territory. Except as otherwise provided below in this Section 19.4(b), the Agreement shall continue in full force and effect with respect to the IL-1 Antibody Product through the applicable notice period set forth above (the "IL-1 Antibody Termination Notice Period"), provided that Regeneron shall not be required to pay to Novartis any milestone payment in respect of the IL-1 Antibody Product which is achieved during the IL-1
Antibody. Novartis shall be responsible for an amount equal to the product of the aggregate Development Costs for the IL-1 Antibody Product in the Co-Commercialization Countries for NAFTA for the relevant calendar quarter multiplied by fifty-five percent (55%), and Regeneron shall be responsible for an amount equal to the product of the aggregate Development Costs for the IL-1 Antibody Product in the Co-Commercialization Countries in NAFTA for the relevant calendar quarter multiplied by forty-five percent (45%). In the event that a Party has incurred less than its applicable percentage share of such Development Costs for an applicable calendar quarter, then, pursuant to Section 9.2(a), such Party shall reimburse the other Party in such amount as is necessary to result in each Party bearing its applicable share of such Development Costs for such calendar quarter.
Antibody. With respect to the IL-1 Antibody, all rights not specifically granted herein to Regeneron are expressly reserved to Novartis. For the avoidance of doubt, Novartis reserves all right, title and ownership to [*********************]. Nothing in this Agreement shall be interpreted as granting to Regeneron any rights with respect to [****************************************].